A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.
A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.
复制标题
免疫检查点抑制剂作为孤立性脑转移治疗后辅助治疗的多中心分析。
DOI：
10.1002/onco.13608
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Johnson,DouglasB
中科院分区：
文献类型：
--
作者：
RandallPatrinelyJr.,,J;Funck-Brentano,Elisa;Nguyen,Khang;Rapisuwon,Suthee;Salem,Joe-Elie;Gibney,GeoffreyT;Carlino,Matteo;Johnson,DouglasB
背景这项工作的目的是描述接受局部治疗和免疫检查点抑制剂 (ICI) 治疗的孤立性脑转移患者的结局。材料和方法来自四个医疗中心的患者，如果他们患有孤立性脑转移瘤，接受局部治疗并接受 ICI 辅助治疗。结果 11 名患者，最大脑转移瘤的中位尺寸为 3.9 cm，接受手术切除 (n= 8) 和/或立体定向放射外科治疗(SRS；n=≥6)，被包括在内。伊匹单抗/纳武单抗是 4 名患者使用的辅助 ICI，其中 1 名患者复发（25%），无死亡，而在 ICI 单药辅助治疗后，7 名患者中有 3 名复发（43%），7 名患者中有 2 名死亡（29%）。所有复发均发生在颅内。 结论 采用手术或 SRS 治疗的孤立性脑转移患者似乎受益于辅助 ICI 治疗，特别是联合治疗。这种情况下的复发似乎主要发生在颅内。
BackgroundThe objective of this work was to characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy.Materials and MethodsPatients from four medical centers were included if they presented with isolated brain metastases treated with local therapy and received adjuvant treatment with ICIs.ResultsEleven patients with median size of largest brain metastasis of 3.9 cm, treated with surgical resection (n= 8) and/or stereotactic radiosurgery (SRS;n= 6), were included. Ipilimumab/nivolumab was the adjuvant ICI used in four patients, of whom one recurred (25%) and none died, compared with three of seven (43%) who recurred and two of seven (29%) who died following adjuvant treatment with ICI monotherapy. All recurrences were intracranial.ConclusionPatients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI therapy, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially.